• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form 4 filed by Ryan Barbara

    5/22/23 8:07:09 PM ET
    $INVO
    Medical/Dental Instruments
    Health Care
    Get the next $INVO alert in real time by email
    SEC FORM 4 SEC Form 4
    FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549

    STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

    Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
    or Section 30(h) of the Investment Company Act of 1940
    OMB APPROVAL
    OMB Number: 3235-0287
    Estimated average burden
    hours per response: 0.5
      
    Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
    1. Name and Address of Reporting Person*
    Ryan Barbara

    (Last) (First) (Middle)
    C/O INVO BIOSCIENCE, INC.
    5582 BROADCAST COURT

    (Street)
    SARASOTA FL 34240

    (City) (State) (Zip)
    2. Issuer Name and Ticker or Trading Symbol
    INVO Bioscience, Inc. [ INVO ]
    5. Relationship of Reporting Person(s) to Issuer
    (Check all applicable)
    X Director 10% Owner
    Officer (give title below) Other (specify below)
    3. Date of Earliest Transaction (Month/Day/Year)
    05/18/2023
    4. If Amendment, Date of Original Filed (Month/Day/Year)
    6. Individual or Joint/Group Filing (Check Applicable Line)
    X Form filed by One Reporting Person
    Form filed by More than One Reporting Person
    Rule 10b5-1(c) Transaction Indication

      
    Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
    Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
    1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
    Code V Amount (A) or (D) Price
    Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
    (e.g., puts, calls, warrants, options, convertible securities)
    1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
    Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
    Stock Option (right to buy) $0.368 05/18/2023 A 85,000 (1) 05/17/2033 Common Stock 85,000 $0 85,000 D
    Explanation of Responses:
    1. The option vests in four equal installments beginning on May 17, 2023 and on each calendar quarter-end thereafter until fully vested.
    /s/ Barbara Ryan 05/22/2023
    ** Signature of Reporting Person Date
    Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
    * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
    ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
    Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
    Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
    Get the next $INVO alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $INVO

    DatePrice TargetRatingAnalyst
    1/19/2022$7.00Buy
    Maxim Group
    8/18/2021$5.75 → $5.25Buy
    Roth Capital
    More analyst ratings

    $INVO
    Financials

    Live finance-specific insights

    See more
    • INVO Reports Record Third Quarter 2023 Financial Results

      Company Expects to Host Conference Call Shortly After November 20, 2023 Following the Progress of Certain Closing Conditions Pertaining to the Announced Merger Agreement with NAYA Biosciences SARASOTA, Fla., Nov. 13, 2023 /PRNewswire/ -- INVO Bioscience, Inc. (NASDAQ:INVO) ("INVO" or the "Company"), a healthcare services fertility company focused on expanding access to advanced treatment worldwide with its INVOcell® medical device and the intravaginal culture ("IVC") procedure it enables, today announced financial results for the third quarter ended September 30, 2023 and provided a business update.

      11/13/23 4:01:00 PM ET
      $INVO
      Medical/Dental Instruments
      Health Care
    • INVO to Report Second Quarter 2023 Financial Results on Monday, August 14, 2023

      Financial results to be released after market close; Conference call to be conducted at 4:30 pm ET SARASOTA, Fla., Aug. 9, 2023 /PRNewswire/ -- INVO Bioscience, Inc. (NASDAQ:INVO), a healthcare services fertility company focused on expanding access to advanced treatment worldwide with its INVOcell® medical device and the intravaginal culture ("IVC") procedure it enables, will report financial results for its second quarter 2023, for the period ended June 30, 2023, after the market close on Monday, August 14, 2023. The Company has scheduled a conference call that same day, Monday, August 14, 2023, at 4:30 pm ET, to review the results.

      8/9/23 4:15:00 PM ET
      $INVO
      Medical/Dental Instruments
      Health Care
    • INVO Bioscience to Report First Quarter 2023 Financial Results on Monday, May 15, 2023

      Financial results to be released after market close; Conference call to be conducted at 4:30 pm ET SARASOTA, Fla., May 8, 2023 /PRNewswire/ -- INVO Bioscience, Inc. (NASDAQ:INVO), a commercial-stage fertility company focused on expanding access to advanced infertility treatment worldwide with its INVOcell® medical device and the intravaginal culture ("IVC") procedure it enables, will report financial results for its first quarter 2023, for the period ended March 31, 2023, after the market close on Monday, May 15, 2023. The Company has scheduled a conference call that same day, Monday, May 15, 2023, at 4:30 pm ET, to review the results.

      5/8/23 4:15:00 PM ET
      $INVO
      Medical/Dental Instruments
      Health Care

    $INVO
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13G/A filed by INVO BioScience Inc. (Amendment)

      SC 13G/A - INVO Bioscience, Inc. (0001417926) (Subject)

      2/6/24 10:24:52 AM ET
      $INVO
      Medical/Dental Instruments
      Health Care
    • SEC Form SC 13G/A filed by INVO BioScience Inc. (Amendment)

      SC 13G/A - INVO Bioscience, Inc. (0001417926) (Subject)

      9/8/23 4:34:56 PM ET
      $INVO
      Medical/Dental Instruments
      Health Care
    • SEC Form SC 13G filed by INVO BioScience Inc.

      SC 13G - INVO Bioscience, Inc. (0001417926) (Subject)

      8/11/23 4:18:49 PM ET
      $INVO
      Medical/Dental Instruments
      Health Care

    $INVO
    Leadership Updates

    Live Leadership Updates

    See more
    • INVO Bioscience Appoints Barbara Levy as Senior VP, Global Clinical Integration

      SARASOTA, Fla., July 14, 2021 /PRNewswire/ -- INVO Bioscience, Inc. (NASDAQ:INVO), a medical device company focused on commercializing the world's only in vivo Culture System (IVC), INVOcell®, an effective and affordable treatment for patients diagnosed with infertility, today announced the appointment of Barbara Levy, M.D., FACOG, FACS as the Company's Senior VP, Global Clinical Integration. Dr. Levy is considered one of the most influential clinical executives in the world, recently serving as Vice President, Health Policy at the American College of Obstetricians and Gynecologists (ACOG) and chair of the American Medical Association/Specialty Society Relative Value Scale Update Committee.

      7/14/21 8:30:00 AM ET
      $INVO
      Medical/Dental Instruments
      Health Care
    • INVO Bioscience Appoints Andrea Goren as Chief Financial Officer

      SARASOTA, Fla., June 15, 2021 /PRNewswire/ -- INVO Bioscience, Inc. (NASDAQ:INVO), a medical device company focused on commercializing the world's only in vivo Intravaginal Culture System (IVC), INVOcell®, an effective and affordable treatment for patients diagnosed with infertility, today announced the appointment of Andrea Goren as the Company's chief financial officer. In a career approaching 27 years, Mr. Goren has extensive experience in numerous financial functions, including service as a public company CFO, company director, capital raising activities as well as mergers

      6/15/21 9:00:00 AM ET
      $INVO
      Medical/Dental Instruments
      Health Care
    • INVO Bioscience Appoints Meryle Lynn Chamberlain to Lead Marketing for Global Brand Expansion

      SARASOTA, Fla., May 10, 2021 /PRNewswire/ -- INVO Bioscience, Inc. (NASDAQ:INVO), a medical device company focused on commercializing the world's only in vivo Intravaginal Culture System (IVC), INVOcell®, an effective and affordable treatment for patients diagnosed with infertility, is pleased to announce the appointment of tenured women's health & fertility solution marketing professional, Meryle Lynn Chamberlain, as Director of Marketing, a newly created position within the company. Chamberlain brings over 15 years of marketing experience in the women's health field includi

      5/10/21 8:30:00 AM ET
      $INVO
      Medical/Dental Instruments
      Health Care

    $INVO
    SEC Filings

    See more
    • SEC Form RW filed by INVO BioScience Inc.

      RW - NAYA Biosciences, Inc. (0001417926) (Filer)

      10/22/24 12:05:35 PM ET
      $INVO
      Medical/Dental Instruments
      Health Care
    • INVO BioScience Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Completion of Acquisition or Disposition of Assets, Unregistered Sales of Equity Securities, Leadership Update, Other Events, Financial Statements and Exhibits

      8-K - INVO Bioscience, Inc. (0001417926) (Filer)

      10/15/24 9:17:59 AM ET
      $INVO
      Medical/Dental Instruments
      Health Care
    • INVO BioScience Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Creation of a Direct Financial Obligation, Financial Statements and Exhibits

      8-K - INVO Bioscience, Inc. (0001417926) (Filer)

      10/1/24 5:26:10 PM ET
      $INVO
      Medical/Dental Instruments
      Health Care

    $INVO
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Maxim Group initiated coverage on INVO Bioscience with a new price target

      Maxim Group initiated coverage of INVO Bioscience with a rating of Buy and set a new price target of $7.00

      1/19/22 8:21:04 AM ET
      $INVO
      Medical/Dental Instruments
      Health Care
    • Roth Capital reiterated coverage on INVO Bioscience with a new price target

      Roth Capital reiterated coverage of INVO Bioscience with a rating of Buy and set a new price target of $5.25 from $5.75 previously

      8/18/21 9:28:21 AM ET
      $INVO
      Medical/Dental Instruments
      Health Care

    $INVO
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • NAYA Biosciences Announces Initiation of Phase 1/2a Clinical Trial for its GPC3-targeted NK Engager Bispecific Antibody in Patients with Hepatocellular Carcinoma

      SARASOTA, Fla. and MIAMI, Oct. 24, 2024 (GLOBE NEWSWIRE) -- NAYA Biosciences ("NAYA") (NASDAQ:NAYA), a life science portfolio company dedicated to bringing breakthrough treatments to patients in oncology, autoimmune diseases, and fertility, today announced an update regarding its clinic trial plans. The Company received regulatory approval from the Israeli Ministry of Health in July 2024 and subsequent institutional review board clearance to initiate patient enrollment in up to 7 academic centers for its clinical trial evaluating the safety and efficacy of NY-303, its GPC3-targeting NK Engager bispecific antibody, as a monotherapy for the treatment of hepatocellular carcinoma in patients n

      10/24/24 9:00:00 AM ET
      $INVO
      $NAYA
      Medical/Dental Instruments
      Health Care
    • INVO Bioscience Confirms Corporate Name Change and New Trading Symbol in Connection with Its Recent Merger with NAYA Biosciences

      SARASOTA, Fla. and MIAMI, Oct. 21, 2024 (GLOBE NEWSWIRE) -- INVO Biosciences (NASDAQ:INVO), a company focused on expanding its portfolio of clinical and commercial-stage assets in fertility, oncology, and autoimmune diseases through the merger of INVO Biosciences and NAYA Biosciences, today confirmed it has changed its corporate name to NAYA Biosciences Inc. and will begin trading under the new symbol "NAYA" at the market open on Tuesday, October 22, 2024. The CUSIP number for the Company's common stock will remain unchanged. The name and symbol change follows the Company's recent announcement on October 14th regarding the completion of its merger with NAYA Biosciences. The newly combine

      10/21/24 9:00:00 AM ET
      $INVO
      Medical/Dental Instruments
      Health Care
    • INVO Bioscience and NAYA Biosciences Close Merger, Combined Company to Operate as NAYA Biosciences (NASDAQ: NAYA)

      SARASOTA, Fla. and MIAMI, Oct. 14, 2024 (GLOBE NEWSWIRE) -- INVO Bioscience ("INVO") (NASDAQ:INVO) today announced it has closed its merger with NAYA Biosciences, a company dedicated to increasing patient access to breakthrough treatments in oncology and autoimmune diseases. The combined company expects to change its name to NAYA Biosciences and trade on the NASDAQ under the "NAYA" ticker. The combined company will continue to operate the revenue-generating fertility business as well as expand its focus to the development of first-in-class clinical-stage assets in oncology and autoimmune diseases. The combined company will be led by INVO Chief Executive Officer Steve Shum, INVO Chief Fina

      10/14/24 9:18:20 AM ET
      $INVO
      Medical/Dental Instruments
      Health Care

    $INVO
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • SEC Form 4 filed by Szot Matthew K

      4 - INVO Bioscience, Inc. (0001417926) (Issuer)

      5/22/23 8:13:16 PM ET
      $INVO
      Medical/Dental Instruments
      Health Care
    • SEC Form 4 filed by Shum Steve

      4 - INVO Bioscience, Inc. (0001417926) (Issuer)

      5/22/23 8:09:50 PM ET
      $INVO
      Medical/Dental Instruments
      Health Care
    • SEC Form 4 filed by Ryan Barbara

      4 - INVO Bioscience, Inc. (0001417926) (Issuer)

      5/22/23 8:07:09 PM ET
      $INVO
      Medical/Dental Instruments
      Health Care